Open AccessExpression of the SART‐1 Antigens in Uterine Cancers
Author(s) -
Matsumoto Hajime,
Shichijo Shigeki,
Kawano Kouichiro,
Nishida Takashi,
Sakamoto Masaru,
Itoh Kyogo
Publication year - 1998
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1998.tb00526.x
Subject(s) - antigen , uterine cancer , cytotoxic t cell , cancer , biology , uterus , cancer research , in utero , pathology , human leukocyte antigen , immunology , medicine , endocrinology , in vitro , genetics , fetus , pregnancy
We recently reported that the SART‐1 gene, encoding the SART‐1 259 tumor antigen which is recognized by HLA‐A26‐restricted cytotoxic T lymphocytes (CTLs), is expressed in the cytosol of squamous cell carcinomas and adenocarcinomas. The present study deals with the expression of SART‐1 259 and SART‐1 800 antigens in uterine cancers. The SART‐1 259 antigen was detected in the cytosol fraction of 4 of 8 uterine cancer cell lines, 24 of 74 (32%) uterine cancer tissues, 0 of 7 uterine myomas, and 0 of 5 non‐tumorous uterine tissues. The SART‐1 800 antigen was expressed in the nuclear fraction of all the uterine cancer cell lines, 41 of 74 (55%) uterine cancer tissues, 0 of 7 myomas, and 3 of 5 non‐tumorous uterine tissues. The SART‐1 259 + uterine cancer cells were recognized by HLA‐A24 restricted and SART‐1 specific CTLs. Therefore, SART‐1 259 antigen could be an appropriate vaccine candidate for a relatively large number of uterine cancer patients.